Interphase FISH in plasma cell dyscrasia: increase in abnormality detection with plasma cell enrichment

Cancer Genetics and Cytogenetics

Volumn 189, Issue 2, 2009, Pages 112-117

  Pozdnyakova, Olga ^a   Crowley Larsen, Patricia ^a   Zota, Victor ^a   Wang, Sa A ^b   Miron, Patricia M ^a  

^a UMASS MEMORIAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SYNDECAN 1;

ARTICLE; BONE MARROW CULTURE; CHROMOSOME ANALYSIS; CHROMOSOME DISORDER; CHROMOSOME REARRANGEMENT; CLINICAL ARTICLE; CONTROLLED STUDY; DIPLOIDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; HUMAN; HUMAN CELL; IMMUNOMAGNETIC SEPARATION; INTERPHASE; KARYOTYPING; PLASMA CELL DYSCRASIA; PRIORITY JOURNAL;

BLOOD CELL COUNT; CELL PROLIFERATION; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 13; CHROMOSOMES, HUMAN, PAIR 17; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INTERPHASE; PARAPROTEINEMIAS; PLASMA CELLS; SENSITIVITY AND SPECIFICITY;

EID: 59849092902     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2008.11.007     Document Type: Article

References (22)

1. In: Jaffe E.S., Harris N.L., Stein H., and Vardiman J.W. (Eds). Pathology and genetics of tumours of haematopoietic and lymphoid tissues. World Health Organization Classification of Tumours (2001), IARC Press, Lyon
2. Dewald G.W., Kyle R.A., Hicks G.A., and Greipp P.R. The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood 66 (1985) 380-390
3. Gould J., Alexanian R., Goodacre A., Pathak S., Hecht B., and Barlogie B. Plasma cell karyotype in multiple myeloma. Blood 71 (1988) 453-456
4. Sawyer J.R., Waldron J.A., Jagannath S., and Barlogie B. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet 82 (1995) 41-49
5. Nilsson T., Lenhoff S., Turesson I., Rylander L., Mitelman F., Westin J., Höglund M., and Johansson B. Cytogenetic features of multiple myeloma: impact of gender, age, disease phase, culture time, and cytokine stimulation. Eur J Haematol 68 (2002) 345-353
6. Fonseca R., Barlogie B., Bataille R., Bastard C., Bergsagel P.L., Chesi M., Davies F.E., Drach J., Greipp P.R., Kirsch I.R., Kuehl W.M., Hernandez J.M., Minvielle S., Pilarski L.M., Shaughnessy Jr. J.D., Stewart A.K., and Avet-Loiseau H. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 64 (2004) 1546-1558
7. Stewart A.K., and Fonseca R. Prognostic and therapeutic significance of myeloma genetics and gene expression profiling. J Clin Oncol 23 (2005) 6339-6344
8. Tricot G.J. New insights into role of microenvironment in multiple myeloma. Int J Hematol 76 Suppl. 1 (2002) 334-336
9. Fonseca R., Blood E., Rue M., Harrington D., Oken M.M., Kyle R.A., Dewald G.W., Van Ness B., Van Wier S.A., Henderson K.J., Bailey R.J., and Greipp P.R. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 101 (2003) 4569-4575
10. Chiecchio L., Protheroe R.K., Ibrahim A.H., Cheung K.L., Rudduck C., Dagrada G.P., Cabanas E.D., Parker T., Nightingale M., Wechalekar A., Orchard K.H., Harrison C.J., Cross N.C., Morgan G.J., and Ross F.M. Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. Leukemia 20 (2006) 1610-1617
11. Zhan F., Sawyer J., and Tricot G. The role of cytogenetics in myeloma. Leukemia 20 (2006) 1484-1486
12. Zandecki M., Lai J.L., and Facon T. Multiple myeloma: almost all patients are cytogenetically abnormal. Br J Haematol 94 (1996) 217-227
13. Terpos E., Eleutherakis-Papaiakovou V., and Dimopoulos M.A. Clinical implications of chromosomal abnormalities in multiple myeloma. Leuk Lymphoma 47 (2006) 803-814
14. Fonseca R., Bailey R.J., Ahmann G.J., Rajkumar S.V., Hoyer J.D., Lust J.A., Kyle R.A., Gertz M.A., Greipp P.R., and Dewald G.W. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood 100 (2002) 1417-1424
15. Nickenig C., Lang N.K., Schoch C., Hiddemann W., and Haferlach T. New insights into the biology of multiple myeloma using a combination of May-Grünwald-Giemsa staining and fluorescence in situ hybridization techniques at the single cell level. Ann Hematol 80 (2001) 662-668
16. Tai Y.T., Teoh G., Shima Y., Chauhan D., Treon S.P., Raje N., Hideshima T., Davies F.E., and Anderson K.C. Isolation and characterization of human multiple myeloma cell enriched populations. J Immunol Methods 235 (2000) 11-19
17. Draube A., Pfister R., Vockerodt M., Schuster S., Kube D., Diehl V., and Tesch H. Immunomagnetic enrichment of CD138 positive cells from weakly infiltrated myeloma patients samples enables the determination of the tumor clone specific IgH rearrangement. Ann Hematol 80 (2001) 83-89
18. Zhan F., Hardin J., Kordsmeier B., Bumm K., Zheng M., Tian E., Sanderson R., Yang Y., Wilson C., Zangari M., Anaissie E., Morris C., Muwalla F., van Rhee F., Fassas A., Crowley J., Tricot G., Barlogie B., and Shaughnessy Jr. J. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 99 (2002) 1745-1757
19. Wuilleme S., Robillard N., Lodé L., Magrangeas F., Beris H., Harousseau J.L., Proffitt J., Minvielle S., and Avet-Loiseau H. Intergroupe Francophone de Myélome. Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma. Leukemia 19 (2005) 275-278
20. Harrison C.J., Mazzullo H., Cheung K.L., Gerrard G., Jalali G.R., Mehta A., Osier D.G., and Orchard K.H. Cytogenetics of multiple myeloma: interpretation of fluorescence in situ hybridization results. Br J Haematol 120 (2003) 944-952
21. In: Barch M.J., Knutsen T., and Spurbeck J.L. (Eds). The AGT cytogenetics laboratory manual. 3rd ed (1997), Lippincott-Raven, Philadelphia
22. Christensen J.H., Abildgaard N., Plesner T., Nibe A., Nielsen O., Sørensen A.G., and Kerndrup G.B. Leukemia/Lymphoma Study Group, Region of Southern Denmark Interphase fluorescence in situ hybridization in multiple myeloma and monoclonal gammopathy of undetermined significance without and with positive plasma cell identification: analysis of 192 cases from the Region of Southern Denmark. Cancer Genet Cytogenet 174 (2007) 89-99